Safety of ultrarush immunotherapy

Dae Hyun Lim

doi:10.4168/aard.2017.5.6.305

Journal List > Allergy Asthma Respir Dis > v.5(6) > 1059280

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lim: Safety of ultrarush immunotherapy

Editorial

Allergy, Asthma & Respiratory Disease 2017; 5(6): 305-306.

Published online: 30 November 2017

DOI: https://doi.org/10.4168/aard.2017.5.6.305

Safety of ultrarush immunotherapy

Dae Hyun Lim

Department of Pediatrics, Inha University School of Medicine, Incheon, Korea.

Correspondence to: Dae Hyun Lim. Department of Pediatrics, Inha University School of Medicine, 366 Seohae-daero, Jung-gu, Incheon 22332, Korea. Tel: +82-32-890-3658, Fax: +82-32-890-2629, dhyunlim@inha.ac.kr

Received 20 October 2017 Revised 8 November 2017 Accepted 8 November 2017

The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

References

1. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004; 92:409–413.

2. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000; 55:484–488.

3. Akmanlar N, Altintaş DU, Güneşer KS, Yilmaz M, Bingöl G. Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr). 2000; 28:213–218.

4. Nagata M, Yamamoto H, Tabe K, Kimura I, Houya I, Kuramitsu K, et al. Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: changes in in vivo and in vitro responses to HDM. Intern Med. 1993; 32:702–709.

5. Hyun SE, Kim HY, Kwak JH, Shin YH, Seo JY, Han MY. Safety and efficacy of the ultra-rush immunotherapy with extracts of Dermatophagoides pteronyssinus in children. Korean J Pediatr. 2008; 51:868–873.

6. Kim ME, Kim JE, Sung JM, Lee JW, Choi GS, Nahm DH. Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis. J Korean Med Sci. 2011; 26:1159–1164.

7. Cho SW, Lee GM, Park JS, Kwan JW, Kim JK. Safety of ultrarush allergen subcutaneous immunotherapy in children with allergic disease. Allergy Asthma Respir Dis. 2017; 5:336–343.

8. Winslow AW, Turbyville JC, Sublett JW, Sublett JL, Pollard SJ. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2016; 117:542–545.

9. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117:134–140.

10. Cardona R, Lopez E, Beltrán J, Sánchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014; 42:90–95.

11. Morais-Almeida M, Arêde C, Sampaio G, Borrego LM. Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age. Asia Pac Allergy. 2016; 6:35–42.

TOOLS

ORCID iDs: Dae Hyun Lim
https://orcid.org/0000-0002-4558-3284
Similar articles